Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | PARP14 | Q460N5 | 3/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582807 | 0.90 | NPC1 (0.54) | NPC1RAB9AMAOAALDH1A1HPGD | |
| SCHEMBL21393161 | 0.80 | BTK (0.41) | NPC1RAB9AALDH1A1GAAKDM4E | |
| SCHEMBL4815159 | 0.79 | ALDH1A1 (0.55) | ALDH1A1HPGDGAAKDM4EHSD17B10 | |
| SCHEMBL8312394 | 0.79 | RAB9A (0.46) | NPC1RAB9AMAOAALDH1A1HPGD | |
| SCHEMBL1658824 | 0.79 | BAZ2B (0.43) | NPC1RAB9AMAOAALDH1A1HPGD | |
| SCHEMBL7581652 | 0.78 | PARP1 (0.56) | NPC1RAB9AMAOAALDH1A1HPGD | |
| SCHEMBL15300166 | 0.78 | BAZ2B (0.42) | NPC1RAB9AMAOAALDH1A1HPGD | |
| SCHEMBL30957414 | 0.78 | BAZ2B (0.42) | NPC1RAB9AMAOAALDH1A1HPGD | |
| SCHEMBL5582059 | 0.78 | BAZ2B (0.46) | NPC1RAB9AMAOAALDH1A1HPGD | |
| SCHEMBL5582929 | 0.76 | TYR (0.50) | NPC1RAB9AMAOAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| EP-0752991-B1 | IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONES ANTAGONISTS OF AMPA AND NMDA RECEPTORS | RHONE POULENC RORER SA (FR) | 1999-05-26 | — | — | EP | disclosed |
| US-5789406-A | Indeno 1,2-E!pyrazine-4-ones, their preparation and the medicaments containing them | RHONE-POULENC RORER S.A. (FR) | 1998-08-04 | — | — | US | disclosed |
| EP-0752991-A1 | INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995026349-A1 | INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1995-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | NPC1 3037/4885RAB9A 2541/4885MAOA 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.